The pharmaceutical sector is forecast to be worth $1.5 trillion by 2023. This growth is set to continue due to a rapidly ageing population in the West and increasing levels of wealth in developing countries.
Pharmaceutical supply chains have rapidly evolved over recent years in response to supply chain disruptions triggered by global political tensions and the Covid pandemic. The rise in the use of biologics, with their sophisticated and high value nature, are also a huge driver of change for the market.
Our latest whitepaper provides an examination of the current and future state of ‘big pharma’, and evaluates the potential for a ‘local supply chain’ to become the favoured biologics business model.
Please enter your details below to download the free whitepaper:
